阿爾法認知將在阿爾茨海默病協會國際會議上展示ZUNVEYL®（苯甲酸加蘭他敏）研究數據Alpha Cognition to Present ZUNVEYL® (Benzgalantamine) Study Data at Alzheimer’s Association International Conference

動脈網

07/08

VANCOUVER, BC and Dallas, TX – July 8 2025, Alpha Cognition Inc. (Nasdaq: ACOG) (「Alpha Cognition」 or the 「Company」), a commercial-stage biopharmaceutical company focused on developing therapies for ...

網頁鏈接

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2549473885"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2549473885\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2549473885?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-07-08 20:34","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2549473885","market":"us","top_or_hot":-1,"title":"阿爾法認知將在阿爾茨海默病協會國際會議上展示ZUNVEYL®（苯甲酸加蘭他敏）研究數據Alpha Cognition to Present ZUNVEYL® (Benzgalantamine) Study Data at Alzheimer’s Association International Conference","media":"動脈網","content":"<div>\n<p>VANCOUVER, BC and Dallas, TX – July 8 2025, Alpha Cognition Inc. (Nasdaq: ACOG) (「Alpha Cognition」 or the 「Company」), a commercial-stage biopharmaceutical company focused on developing therapies for ...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708203812979e54ef&s=b\">網頁鏈接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>阿爾法認知將在阿爾茨海默病協會國際會議上展示ZUNVEYL®（苯甲酸加蘭他敏）研究數據Alpha Cognition to Present ZUNVEYL® (Benzgalantamine) Study Data at Alzheimer’s Association International Conference</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n阿爾法認知將在阿爾茨海默病協會國際會議上展示ZUNVEYL®（苯甲酸加蘭他敏）研究數據Alpha Cognition to Present ZUNVEYL® (Benzgalantamine) Study Data at Alzheimer’s Association International Conference\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">動脈網</strong><span class=\"h-time small\">2025-07-08 20:34</span>\n</p>\n</h4>\n</header>\n<article>\n<div>\n<p>VANCOUVER, BC and Dallas, TX – July 8 2025, Alpha Cognition Inc. (Nasdaq: ACOG) (「Alpha Cognition」 or the 「Company」), a commercial-stage biopharmaceutical company focused on developing therapies for ...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708203812979e54ef&s=b\">網頁鏈接</a>\n\n</div>\n\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708203812979e54ef&s=b\">動脈網</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AAIC","symbol_name":"阿靈頓資產投資公司","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708203812979e54ef&s=b","article_id":"2549473885","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708203812979e54ef&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2549473885","pubTimestamp":1751978040,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"VANCOUVER, BC and Dallas, TX – July 8 2025, Alpha Cognition Inc.  , a commercial-stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced it will present new clinical data on ZUNVEYL at the Alzheimer’s Association International Conference , taking place July 27–31, 2025, in Toronto, Canada.温哥華，不列顛哥倫比亞省和德克薩斯州達拉斯——2025年7月8日，阿爾法認知公司，一家專注於開發神經退行性疾病療法的商業階段生物製藥公司，今天宣佈將在2025年7月27日至31日在加拿大多倫多舉行的阿爾茨海默病協會國際會議上展示關於ZUNVEYL的新臨牀數據。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"AAIC":"阿灵顿资产投资公司","BK4110":"抵押房地产投资信托","ACOG":"ALPHA COGNITION INC","BK4139":"生物科技"},"translate_title":"Alpha Cognition to Present ZUNVEYL at Alzheimer's Association International Conference ® (Galantamine Benzoate) Study Data Alpha Cognition to Present ZUNVEYL ® (Benzgalantamine) Study Data at Alzheimer's Association International Conference","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AAIC":1,"ACOG":0.9},"content_text":"VANCOUVER, BC and Dallas, TX – July 8 2025, Alpha Cognition Inc. (Nasdaq: ACOG) (「Alpha Cognition」 or the 「Company」), a commercial-stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced it will present new clinical data on ZUNVEYL at the Alzheimer’s Association International Conference (AAIC), taking place July 27–31, 2025, in Toronto, Canada.温哥華，不列顛哥倫比亞省和德克薩斯州達拉斯——2025年7月8日，阿爾法認知公司（納斯達克股票代碼：ACOG）（「阿爾法認知」或「公司」），一家專注於開發神經退行性疾病療法的商業階段生物製藥公司，今天宣佈將在2025年7月27日至31日在加拿大多倫多舉行的阿爾茨海默病協會國際會議（AAIC）上展示關於ZUNVEYL的新臨牀數據。The Company will share the following poster presentations:.公司將分享以下海報展示：。Bioequivalence of ZUNVEYLZUNVEYL的生物等效性, a Galantamine Prodrug to Galantamine Hydrobromide Extended-Release Demonstrated Under，一種加蘭他敏前藥轉化為加蘭他敏氫溴酸鹽緩釋劑型的表現如下Steady State穩態Conditions (Poster #107147) - July 27條件（海報 #107147） - 7月27日Bioequivalence of ZUNVEYLZUNVEYL的生物等效性, a Galantamine Prodrug to Galantamine Hydrobromide Immediate-Release Demonstrated Under，一種加蘭他敏前藥與鹽酸加蘭他敏速釋製劑的表現Fed and Fasting Conditions (餵養和禁食條件 (Poster#107030) - July 28海報#107030 - 7月28日Dose Proportionality of ZUNVEYLZUNVEYL的劑量比例性, a Galantamine Prodrug, Over a Dosage Range of Five to Fifteen Milligrams Demonstrated Under Fasting Conditions (Poster #107255) -July 30，一種加蘭他敏前藥，在五到十五毫克的劑量範圍內，在空腹條件下展示（海報#107255）- 7月30日「We are excited to present data demonstrating ZUNVEYL’s bioequivalence and dose proportionality,」 said Dr. Denis Kay, Chief Scientific Officer of Alpha Cognition. 「Given the high unmet need and challenges with current treatments, ZUNVEYL has the potential to offer physicians a well-tolerated therapy with compelling clinical benefits.」.「我們很高興展示證明ZUNVEYL生物等效性和劑量比例性的數據，」Alpha Cognition首席科學官丹尼斯·凱博士表示。「鑑於目前治療手段存在的高度未滿足需求和挑戰，ZUNVEYL有潛力為醫生提供一種耐受性良好且具有顯著臨牀益處的療法。」AAIC is the world’s largest forum for dementia research, convening global leaders in basic and clinical science to advance prevention, diagnosis, and treatment of Alzheimer’s disease.AAIC是全球最大的痴呆研究論壇，彙集了基礎科學和臨牀科學的全球領導者，以推進阿爾茨海默病的預防、診斷和治療。About Alpha Cognition Inc.關於阿爾法認知公司Alpha Cognition Inc. is a commercial stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease and cognitive Impairment with mild Traumatic Brain Injury (「mTBI」), for which there are currently no approved treatment options..阿爾法認知公司是一家商業階段的生物製藥公司，致力於為神經退行性疾病患者開發治療方法，例如阿爾茨海默病和輕度創傷性腦損傷 (「mTBI」) 引發的認知障礙，目前尚無獲批的治療選擇。ALPHA-1062 formulated as a delayed release oral tablet (ZUNVEYL), is an FDA approved new generation acetylcholinesterase inhibitor for the treatment of Alzheimer’s disease, with expected minimal gastrointestinal side effects. ZUNVEYL’s active metabolite is differentiated from donepezil and rivastigmine in that it binds neuronal nicotinic receptors, most notably the alpha-7 subtype, which is known to have a positive effect on cognition.阿爾法-1062製成的緩釋口服片劑（ZUNVEYL）是一種FDA批准的新一代乙酰膽鹼酯酶抑制劑，用於治療阿爾茨海默病，預期產生的胃腸道副作用極小。ZUNVEYL的活性代謝物與多奈哌齊和利伐斯的明不同之處在於，它能夠結合神經元煙鹼受體，尤其是α-7亞型，這種亞型對認知功能有積極影響。ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer’s dementia, and as a  sublingual formulation for cognitive Impairment with mTBI..ALPHA-1062 還正與美金剛聯合開發，用於治療中度至重度阿爾茨海默病痴呆，並作為舌下含服制劑用於治療伴有輕度創傷性腦損傷 (mTBI) 的認知障礙。For further information:更多信息請見：Investor Relations投資者關係IR@alphacognition.comIR@alphacognition.comhttps://www.alphacognition.com/https://www.alphacognition.com/INDICATION AND USAGE適應症和用法ZUNVEYL is a cholinesterase inhibitor indicated for the treatment of mild to moderate dementia of the Alzheimer’s type in adults.ZUNVEYL是一種膽鹼酯酶抑制劑，用於治療成人阿爾茨海默型輕度至中度痴呆。IMPORTANT SAFETY INFORMATION重要安全信息CONTRAINDICATIONS禁忌症ZUNVEYL is contraindicated in patients with known hypersensitivity to benzgalantamine, galantamine, or to any inactive ingredients in ZUNVEYL. Serious skin reactions have occurred.對苯扎蘭明、加蘭他敏或ZUNVEYL中任何非活性成分已知過敏的患者禁用ZUNVEYL。已發生嚴重皮膚反應。WARNINGS AND PRECAUTIONS警告和注意事項Serious Skin Reactions嚴重皮膚反應: Serious skin reactions (Stevens-Johnson syndrome and acute generalized exanthematous pustulosis) have been reported in patients receiving galantamine (the active metabolite of ZUNVEYL tablets). If signs or symptoms suggest a serious skin reaction, use of this drug should not be resumed, and alternative therapy should be considered..：接受加蘭他敏（ZUNVEYL片的活性代謝物）治療的患者中已有嚴重皮膚反應（史蒂文斯-約翰遜綜合徵和急性泛發性膿皰病）的報告。如果出現提示嚴重皮膚反應的體徵或症狀，不應繼續使用該藥物，並應考慮替代療法。Anesthesia麻醉: See Drug Interactions Section：參見藥物相互作用部分Cardiovascular Conditions:心血管疾病：Cholinesterase inhibitors, including ZUNVEYL, have vagotonic effects on the sinoatrial and atrioventricular nodes, leading to bradycardia and AV block. Bradycardia and all types of heart block have been reported in patients taking cholinesterase inhibitors, both with and without known underlying cardiac conduction abnormalities.膽鹼酯酶抑制劑，包括ZUNVEYL，對竇房結和房室結有迷走神經緊張作用，導致心動過緩和房室傳導阻滯。據報道，服用膽鹼酯酶抑制劑的患者，無論是否已知存在心臟傳導異常，均出現心動過緩和各種類型的心臟傳導阻滯。Therefore, all patients should be considered at risk for adverse effects on cardiac conduction..因此，所有患者都應被視為對心臟傳導有不良影響的風險。Patients treated with galantamine up to 24 mg/day using the recommended dosing schedule showed a dose-related increase in risk of syncope.使用推薦劑量方案，每天服用高達24毫克加蘭他敏的患者顯示出與劑量相關的暈厥風險增加。Gastrointestinal Conditions胃腸道疾病: Cholinesterase inhibitors, including ZUNVEYL, may increase gastric acid secretion. Patients should be monitored closely for active or occult gastrointestinal bleeding, especially those with a history of ulcer disease or those receiving concurrent nonsteroidal anti-inflammatory drugs (NSAIDs). Clinical studies of galantamine have shown no increase, relative to placebo, in the incidence of either peptic ulcer disease or gastrointestinal bleeding..：包括ZUNVEYL在內的膽鹼酯酶抑制劑可能會增加胃酸分泌。應密切監測患者是否存在活動性或隱匿性胃腸道出血，特別是那些有潰瘍病史或同時接受非甾體抗炎藥（NSAIDs）治療的患者。加蘭他敏的臨牀研究顯示，與安慰劑相比，無論是消化性潰瘍病還是胃腸道出血的發生率均未增加。Galantamine has been shown to produce nausea, vomiting, diarrhea, anorexia, and weight loss加蘭他敏可能會引起噁心、嘔吐、腹瀉、厭食和體重減輕。.。Monitor the patient's weight during therapy with ZUNVEYL.在使用ZUNVEYL治療期間，監測患者的體重。Genitourinary Conditions:泌尿生殖系統疾病:Although this was not observed in clinical trials with galantamine, cholinesterase inhibitors, including ZUNVEYL, may cause bladder outflow obstruction.雖然在加蘭他敏的臨牀試驗中未觀察到這一點，但包括ZUNVEYL在內的膽鹼酯酶抑制劑可能會導致膀胱流出道梗阻。Neurological Conditions:神經系統疾病：Cholinesterase inhibitors are believed to have some potential to cause generalized convulsions. Seizure activity may also be a manifestation of Alzheimer's disease. Patients with Alzheimer's disease should be monitored closely for seizures while taking ZUNVEYL.乙酰膽鹼酯酶抑制劑被認為有引發全身性抽搐的潛在可能。癲癇發作也可能是阿爾茨海默病的一種表現。服用ZUNVEYL期間，應密切監測阿爾茨海默病患者是否出現癲癇發作。Pulmonary Conditions:肺部疾病：Cholinesterase inhibitors, including ZUNVEYL, should be prescribed with care to patients with a history of severe asthma or obstructive pulmonary disease. Monitor for respiratory adverse reactions.包括ZUNVEYL在內的膽鹼酯酶抑制劑，應謹慎開具給有嚴重哮喘或阻塞性肺病史的患者。監測呼吸系統不良反應。ADVERSE REACTIONS不良反應The most common adverse reactions with galantamine tablets (≥5%) were nausea, vomiting, diarrhea, dizziness, headache, and decreased appetite.加蘭他敏片劑最常見的不良反應（≥5%）為噁心、嘔吐、腹瀉、頭暈、頭痛和食慾減退。DRUG INTERACTIONS藥物相互作用Use with Anticholinergics:與抗膽鹼能藥物合用：Galantamine has the potential to interfere with the activity of anticholinergic medications.加蘭他敏有可能干擾抗膽鹼能藥物的活性。Use with Cholinomimetics and Other Cholinesterase Inhibitors:與膽鹼能藥物和其他膽鹼酯酶抑制劑合用：A synergistic effect is expected when cholinesterase inhibitors are given concurrently with succinylcholine, other cholinesterase inhibitors, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.預計當膽鹼酯酶抑制劑與琥珀酰膽鹼、其他膽鹼酯酶抑制劑、類似的神經肌肉阻斷劑或膽鹼能激動劑（如貝膽鹼）同時給藥時，會產生協同效應。USE IN SPECIFIC POPULATIONS特定人羣中的使用Pregnancy:懷孕：Based on animal data may cause fetal harm.基於動物數據，可能引起胎兒傷害。Hepatic Impairment:肝功能損害：In patients with moderate hepatic impairment, a decrease in clearance of galantamine was observed; therefore, a dosage adjustment is recommended. Use of ZUNVEYL in patients with severe hepatic impairment is not recommended.在中度肝功能損害患者中，觀察到加蘭他敏的清除率降低；因此，建議調整劑量。不建議重度肝功能損害患者使用ZUNVEYL。Renal Impairment:腎功能損害:In patients with a creatinine clearance of 9 to 59 mL/min, an increase in exposure of galantamine was observed; therefore, a dosage adjustment is recommended. Use of ZUNVEYL in patients with creatinine clearance less than 9 mL/min is not recommended.在肌酐清除率為 9 至 59 毫升/分鐘的患者中，觀察到加蘭他敏的暴露量增加；因此，建議調整劑量。不建議肌酐清除率低於 9 毫升/分鐘的患者使用 ZUNVEYL。These are not all of the possible side effects of ZUNVEYL. You can report side effects to the FDA. Visit這些並非ZUNVEYL的所有可能副作用。您可以向FDA報告副作用。訪問www.fda.gov/MedWatchwww.fda.gov/MedWatchor call或打電話1‑800‑FDA‑10881‑800‑食品藥品監督管理局‑1088.  Please click here for. 請點擊這裏以獲取Full Prescribing Information完整處方信息.。Forward-looking Statements前瞻性聲明This news release includes forward-looking statements within the meaning of applicable securities laws. Except for statements of historical fact, any information contained in this news release may be a forward‐looking statement that reflects the Company’s current views about future events and are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements.本新聞稿包含適用證券法意義上的前瞻性聲明。除歷史事實陳述外，本新聞稿中包含的任何信息可能為前瞻性聲明，反映了公司對未來事件的當前看法，並受已知和未知風險、不確定性、假設及其他可能導致實際結果、活動水平、表現或成就與這些前瞻性聲明明示或暗示的信息有重大差異的因素影響。In some cases, you can identify forward‐looking statements by the words 「may,」 「might,」 「will,」 「could,」 「would,」 「should,」 「expect,」 「intend,」 「plan,」 「objective,」 「anticipate,」 「believe,」 「estimate,」 「predict,」 「project,」 「potential,」 「target,」 「seek,」 「contemplate,」 「continue」 and 「ongoing,」 or the negative of these terms, or other comparable terminology intended to identify statements about the future.在某些情況下，您可以通過「可能」、「也許」、「將」、「可以」、「會」、「應該」、「預期」、「打算」、「計劃」、「目標」、「預期」、「相信」、「估計」、「預測」、「項目」、「潛力」、「目標」、「尋求」、「考慮」、「繼續」和「正在進行」等詞語，或這些詞語的否定形式，或其他用於識別未來陳述的類似術語來識別前瞻性聲明。Forward‐looking statements may include statements regarding the, the long-term benefits of ZUNVEYL, the Company’s timing and planned activities and business strategy to launch ZUNVEYL, the potential timing for the availability of ZUNVEYL, the potential future developments of ZUNVEYL, the market size and demand for ZUNVEYL and the Company’s potential growth opportunities, capital requirements.前瞻性聲明可能包括關於ZUNVEYL的長期效益、公司推出ZUNVEYL的時間規劃、業務戰略、ZUNVEYL可能的上市時間、ZUNVEYL未來的潛在發展、市場規模和需求以及公司的潛在增長機會和資本需求的聲明。Although the Company believes to have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. The Company cannot assure that the actual results will be consistent with these forward-looking statements.  These forward-looking statements are subject to.儘管公司認為每項前瞻性聲明都有合理的依據，但我們提醒您，這些聲明是基於我們目前已知的事實和因素以及我們對未來的預期，而這些預期並不確定。公司無法保證實際結果將與這些前瞻性聲明一致。這些前瞻性聲明受制於。www.sedar.comwww.sedar.comand the Company’s filings with the United States Securities and Exchange Commission (the 「SEC」), including those risk factors under the heading 「Risk Factors」 in the Company’s Form S-1/A registration statement as filed with the SEC on January 10, 2025 and available at以及公司向美國證券交易委員會（「SEC」）提交的文件，包括公司於2025年1月10日向SEC提交的S-1/A註冊聲明中標題為「風險因素」下的那些風險因素，並可訪問以下網址獲取：www.sec.govwww.sec.gov. These forward‐looking statements speak only as of the date of this news release and the Company undertakes no obligation to revise or update any forward‐looking statements for any reason, even if new information becomes available in the future, except as required by law.這些前瞻性陳述僅截至本新聞稿發佈之日，公司沒有義務出於任何原因修改或更新任何前瞻性陳述，即使未來有新的信息可用，除非法律要求。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease,conferences","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}